Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
By P. Rastogi, S. Anderson, H. Bear, C. Geyer, M. Kahlenberg, A. Robidoux, R. Margolese, J. Hoehn, V. Vogel, S. Dakhil and 8 more. Journal of Clinical Oncology, 2008
1,729 citations recorded by the source corpus.
Subfields: Cancer Research, Pathology and Forensic Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/d564442f6bb3bd01dc116dd38e574c83d5b4329a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
Citations in the corpus
- Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline (2021, background): “in peer-reviewed journals; (2) editorials, commentaries, letters, news articles, case reports, and narrative reviews; (3) published in a non-English language; (4) RCTs with , 100 patients total across treatment arms; (5) trials that evaluated only clinical response, biomarker end points, or breast-c”
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, background): “Primary systemic therapy is indicated for locally advanced breast cancer (stages IIIA–B) including inflammatory breast cancer [III, B] and for large operable tumors for reducing tumor size in order possibly to perform BCS [I, A] [73] and to assess responsiveness to systemic therapy in clinical trial”
- Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. (2009, background): “The rate of 16% in the nondiabetic patients is consistent with other studies of taxane-based neoadjuvant chemotherapy in patients with breast cancer.(1,2,25) The lower rate in the nonmetformin group raises the possibility that other factors particular to this group make the tumors less susceptible t”
- Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis (2020, neutral): “Studies have demonstrated no difference in survival between adjuvant or neoadjuvant setting (1, 2).”
- An overview of triple-negative breast cancer (2016, background): “Various studies of neoadjuvant chemotherapy in TNBC confirmed that pCR can be used as a surrogate marker for long-term response and survival [108].”
- Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. (2012, result): “However, selected trials comparing different neoadjuvant regimens have failed to demonstrate an association between pCR rate and improved outcome.(4) Methodologic limitations are likely to be the reason for this unexpected discrepancy.”